Diabetic ocular complications are a leading PROCEEDINGS MOLECULAR BIOLOGY AND NATURAL HISTORY OF DIABETIC RETINOPATHY * Lloyd P.
|
|
- Suzanna Cunningham
- 6 years ago
- Views:
Transcription
1 MOLECULAR BIOLOGY AND NATURAL HISTORY OF DIABETIC RETINOPATHY * Lloyd P. Aiello, MD, PhD ABSTRACT Diabetic retinopathy is the most common diabetic microvascular complication, affecting approximately 50% of patients with diabetes. During the next 2 decades, the prevalence of diabetes and the impact of diabetic retinopathy (DR) are expected to grow considerably in the United States and around the world. Beginning in the 1950s, a number of clinical trials have characterized the natural history of DR and the efficacy and safety of DR treatment strategies. Even before the onset of clinically evident retinopathy, diabetes is associated with a number of pathologic and biochemical alterations of the retina, including derangements of blood flow, pericyte loss, leukocyte adhesion, and capillary basement membrane thickening. The initial stages of nonproliferative DR (NPDR) are characterized by retinal hemorrhage and microaneurysms. This stage is followed eventually by proliferative DR (PDR), which is characterized by the formation of new retinal blood vessels. Diabetic macular edema (DME) can occur at any stage of DR although it is more likely with more advanced retinopathy. The severity of DR has traditionally been classified using a complex rating system that was developed by the Early Treatment Diabetic Retinopathy Study (ETDRS) investigators. More recently, the American Academy of Ophthalmology has developed a simplified 5-stage rating scale that is more readily applicable to routine clinical use. The severity of DR is an important predictor of retinopathy progression and severe vision loss. The likelihood of progression to PDR within 1 year is approximately 1% for patients with mild NPDR, but about 15% for patients with severe NPDR. In 5 years the rates are 16% and 56%, respectively. Laser therapy can prevent visual loss, especially in patients with PDR, but is associated with a number of potential adverse events, including loss of peripheral vision and night vision, as well as alterations of color perception. More serious adverse events, such as laser burns to the fovea, lens, iris, or cornea, may also occur. Recent advances in understanding the biochemical pathways that cause DR have led to the development of new treatment strategies to prevent the progression to severe vision loss. Protein kinase C (PKC) participates in many physiological processes that contribute to DR, including regulation of retinal blood flow and the production and action of retinal growth factors and cytokines. Emerging preclinical and clinical evidence suggests that pharmacologic agents that inhibit PKC may slow the progression of DR. Other potential therapeutic targets include vascular endothelial growth factor, which promotes the formation of new blood vessels, and agents that inhibit the formation or activity of free radicals. These novel treatment strategies are currently being evaluated in randomized controlled clinical trials. (Adv Stud Ophthalmol. 2005;2(1):8-13) *Based on a presentation given by Dr Aiello at a symposium held during the Annual Meeting of the American Academy of Ophthalmology. Associate Professor of Ophthalmology, Harvard University Medical School; Director of Eye Research, Joslin Diabetes Center, Boston, Massachusetts. Address correspondence to: Lloyd P. Aiello, MD, PhD, One Joslin Place, Boston, MA lloydpaul.aiello@joslin.harvard.edu. Diabetic ocular complications are a leading cause of severe visual loss, moderate visual loss, and new-onset blindness in the United States. 1 They are associated with an annual incidence of cases of proliferative diabetic retinopathy (PDR), 5000 cases of blindness, and a financial impact of $620 mil- 8 Vol. 2, No. 1 May 2005
2 lion. 2-4 An analysis of data from the Behavioral Risk Factor Surveillance System, a nationwide standardized survey conducted by the US Centers for Disease Control and Prevention and health agencies of 42 states, found that 6.5% of the US adult population (approximately 13 million persons) have been diagnosed by a healthcare provider as having diabetes. 5 Another 5.2 million persons have unrecognized diabetes. 6 According to the American Diabetes Association, diabetes is associated with direct medical costs of approximately $44.1 billion per year in the United States, as well as another $54 billion in indirect costs. 7 In 1997, medical expenses incurred by patients with diabetes totaled an average of $ per patient, compared with $2669 per person without diabetes. 6 By 2002, the per-capita costs of diabetes had increased more than 30%, to $ The World Health Organization (WHO) has estimated that by 2025, 22 million Americans may have diabetes, 8 although the actual number may be considerably greater than this. The increasing impact of diabetes is not only a problem in the United States: the WHO has forecast a worldwide increase in the number of adults with diabetes of 122% (from 135 million to 300 million) between 1995 and Diabetic retinopathy is the most common diabetic microvascular complication, affecting approximately 50% of patients. 9 It has been estimated that more than 5 million Americans (approximately 2.5% of the US population) has some degree of diabetic retinopathy (DR), 9 and that diabetes is the most common cause of new legal blindness among US adults. 10 Other common complications of diabetes include diabetic peripheral neuropathy (40% of patients), diabetic nephropathy (35%), and cardiovascular disease (43%). 9 Beginning in the 1950s, a number of clinical trials have provided detailed information regarding the natural history of DR, the rate of DR progression, and the effectiveness of various treatment options. Some of the principal clinical trials of DR include pituitary ablation studies, the Diabetic Retinopathy Study, the Early Treatment Diabetic Retinopathy Study (ETDRS), the Diabetic Retinopathy Vitrectomy Study, the Diabetes Control and Complications Trial, and the United Kingdom Prospective Diabetes Study In addition, recent advances in the understanding of both the natural history and the underlying molecular biology of diabetes have led to the development of potential new therapeutic approaches, and many of these approaches are currently being evaluated in clinical trials. STAGES OF DR The retinal manifestations of diabetes encompass a broad spectrum of microvascular and clinical changes, but are generally divided into 2 broad subdivisions: DR and diabetic macular edema (DME). Even before the appearance of clinically evident DR, a number of pathological changes have begun in the retina, including alterations of retinal blood flow, the appearance of pericyte ghosts, pericyte loss, acellular capillaries, endothelial leukocyte adhesion, thickening of capillary basement membrane, and other biochemical alterations. 17 The progression to nonproliferative diabetic retinopathy (NPDR) is associated with clinical findings of hemorrhage and microaneurysms, intraretinal microvascular anomalies (IRMAs), and venous beading. 18 Further progression results in the appearance of PDR, which is characterized by neovascularization, vitreous hemorrhage, and/or preretinal hemorrhage. 18 DME may develop at any point along this spectrum, although it is more common in more advanced stages of retinopathy. It is important to be able to categorize the stages of retinopathy progression in order to compare research findings across different clinical trials. The severity of DR Table 1. Diabetic Retinopathy Disease Severity Scale Proposed Disease Severity Level Findings Observable on Dilated Ophthalmoscopy No apparent retinopathy No abnormalities Mild nonproliferative Microaneurysms only diabetic retinopathy Moderate nonproliferative More than just microaneurysms but diabetic retinopathy less than severe diabetic retinopathy Severe nonproliferative Any of the following: more than 20 diabetic retinopathy intraretinal hemorrhages in each of 4 quadrants; definite venous beading in 2+ quadrants; prominent intraretinal microvascular abnormalities in 1+ quadrant AND no signs of proliferative retinopathy Proliferative diabetic One or more of the following: retinopathy neovascularization, vitreous/preretinal hemorrhage Reprinted with permission from Wilkinson et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9): Advanced Studies in Ophthalmology 9
3 has traditionally been graded using a rating scale that was first developed in the ETDRS. 18 In this rating scale, NPDR was categorized as mild, moderate, severe, and very severe; and PDR was categorized as less than high risk or high risk. DME was categorized clinically as absent, not clinically significant, or clinically significant. For clinical research purposes, a more detailed and complex rating scale was developed that included 13 categories and 2 subcategories. 19 However, many clinicians feel that these complex rating scales were not well suited for routine clinical use because of the number of DR stages and the complexity of the ratings for each stage, as well as the need to use standard photographs for grading. 20 Recently there has been an effort by the American Academy of Ophthalmology to simplify the ratings of DR using an internationally recognized scale. 20 This classification is summarized in Table 1. Although the risk of progression is similar for patients with no apparent DR and with mild NPDR, this rating scale distinguishes between the 2 conditions because it is often helpful for patients to realize that they have begun to develop clinically evident retinopathy. Severe NPDR is classified using the 4:2:1 rule (20 or more intraretinal hemorrhages in each of the 4 quadrants; or definite bleeding in 2 or more quadrants; or prominent IRMAs in 1 or more quadrants). Many clinicians would prefer a definition of severe NPDR that does include analysis of IRMAs. However, IRMAs have been found to be highly associated with advanced disease, 20 and it is therefore important that clinicians learn to identify them. The relationship between this new proposed international DR rating scale and the corresponding ETDRS levels are shown in Table 2. In this new classification system, DME is now divided into 2 categories, apparently absent (no apparent retinal thickening or hard exudates in the posterior pole), or apparently present (some degree of retinal thickening or hard exudates in the posterior pole). 20 When present, DME may be subdivided as mild (some retinal thickening or hard exudates in the posterior pole but distant from the center of the macula); moderate (retinal thickening or hard exudates approaching the center of the macula but not involving the center); or severe (retinal thickening or hard exudates involving the center of the macula). The level of retinopathy is highly correlated with subsequent disease progression. In the ETDRS, the rate of progression was examined for patients with mild, moderate, or severe NPDR at baseline. Approximately 1% of patients with mild NPDR at baseline developed high-risk characteristics for PDR within 1 year and 16% at 5 years. 2 Approximately 15% of patients with severe NPDR at baseline developed high-risk characteristics in 1 year while 56% developed high-risk PDR within 5 years. For patients with very severe NPDR at baseline, the numbers are even higher: 45% and 71%, respectively. Thus, information about the baseline level of retinopathy is important to help set schedules for follow-up eye examinations. Increasing severity of DR at baseline is also associated with increasing progression to sight-threatening disease and the need to see the patient more frequently. 21 LASER-BASED TREATMENT Panretinal laser photocoagulation can be effective for the treatment of DR, especially for PDR. Severe vision loss (visual acuity <5/200) develops in 20% to 30% of untreated eyes, but in fewer than 5% of treated eyes. 2 For DME, current treatments are not quite as beneficial. Focal photocoagulation produces approximately a 50% reduction in moderate visual loss on average, compared with deferral of photocoagulation, in eyes with clinically significant macular edema. However, vision already lost is usually not restored. 13 There are significant limitations to the available laser-based therapies. Laser treatment is not effective for every patient, and it partially destroys the retina in an effort to pre- Table 2. International Clinical DR Scale Compared with ETDRS Level of DR International Classification ETDRS Level No apparent retinopathy Level 10; DR absent Mild NPDR Level 20; mild NPDR Moderate NPDR Levels 35, 43, 47; moderate NPDR Severe NPDR Levels 53A-E; severe to very severe NPDR PDR Levels 61, 65, 71, 75, 81, 85; PDR, high-risk PDR, very severe PDR DR = diabetic retinopathy; ETDRS = Early Treatment Diabetic Retinopathy Study; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy. Adapted with permission from Wilkinson et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9): Vol. 2, No. 1 May 2005
4 serve vision. Side effects of treatment include loss of peripheral vision or night vision, as well as altered color perception. 22 Other potential complications include burns to the fovea, lens, iris, or cornea; burns spread through the macula; choroidal effusions; and angle-closure glaucoma. Therefore, novel therapies are needed for DR to prevent the development of PDR, the progression of DME, and the progression to NPDR. MOLECULAR BIOLOGY OF DR Understanding of the molecular biology underlying DR has increased substantially during the last decade. This knowledge has spawned the development of several novel therapeutic approaches. Four major metabolic pathways have been described by which hyperglycemia results in the activation of cellular signaling molecules that alter gene expression or protein function, resulting in retinopathy and other microvascular complications of diabetes (Figure). 23 The aldose reductase pathway is a 2-step metabolic process in which intracellular glucose is first converted to sorbitol by the enzyme aldose reductase, and sorbitol is then converted to fructose by the enzyme sorbitol dehydrogenase. In the advanced glycation endproduct (AGE) pathway, the function of cellular proteins is disrupted by covalent modification and cross-linking of protein molecules by excessive glucose. In the reactive oxygen intermediate pathway, high levels of glucose result in the formation of toxic free radicals produced by mitochondrial energy metabolism. Each of these 3 pathways is hypothesized to result in the accumulation of reactive metabolites that contribute to widespread cellular injury. A fourth pathway, activation of protein kinase C (PKC) is involved in many aspects of vascular regulation that are potentially important in retinal injury in diabetes, including vascular permeability, vasodilation, and growth factor activity. The identification of these biochemical pathways has led to the development of specific strategies to intervene and prevent the development of injury. For example, the aldose reductase pathway may be blocked by aldose reductase inhibitors; the AGE pathway may be blocked by soluble AGE receptors (soluble RAGE); reactive oxygen species may be inhibited by antioxidants; and the effects of PKC activation may be ameliorated by PKC inhibitors. 23 PKC has received considerable recent attention in the pathogenesis and treatment of diabetic microvascular complications because it produces a number of physiological effects that are thought to contribute to the features of retinal injury that were described previously (eg, pericyte loss, acellular capillaries, microaneurysms). 23 PKC is a serine/threonine protein kinase that is found in the eye and in other tissues throughout the body. 24 It is a G-protein coupled receptor that is activated by diacylglycerol. 25 In hyperglycemia, the production of palmitate and oleate stimulate de novo synthesis of diacylgycerol. 25 Diacylglycerol activates PKC (especially the PKC-β and PKC-δ isoforms), which produces its physiological effects by phosphorylating proteins. 24 PKC affects retinal blood flow due to effects on endothelin-1 expression, angiotensin, and nitric oxide. 25 It increases vascular permeability and stimulates the production and mediates the action of growth factors such as vascular endothelial growth factor (VEGF) and transforming growth factor β (TGF-β). 25 TGF-β is important in the increase in basement membrane protein synthesis, which is characteristic of early diabetes in the eye and elsewhere. VEGF is especially important in neovascularization and in retinal leakage that contributes to DME. 24 PKC also stimulates the adhesion of leukocytes to the vascular endothelium. 24 Evidence from animal models and clinical studies demonstrates the importance of PKC in the develop- Figure. Four Major Pathways for Glucose-Induced Cellular Damage AR Inhibitors Soluble RAGE Antioxidants Aldose Reductase Pathway PKC Isoform Inhibitors Abnormal Angiogenesis Abnormal Cell Growth and Survival Aminoguanidine Hyperglycemia Advanced Glycation Endproduct Pathway Reactive Oxygen Intermediate Pathway Glucotoxins (eg, Reactive Metabolites) Activation of Cell Signaling Molecules Altered Gene Expression Cellular Dysfunction and Damage Hyperpermeability Basement Matrix Thickening Abnormal Blood Flow Increased Leukocyte Adhesion Protein Kinase C Pathway Altered Protein Function Contractility Cardiomyopathy Thrombosis AR = aldose reductase; RAGE = advanced glycation endproduct receptors. Adapted with permission from Sheetz et al. Molecular understanding of hyperglycemia s adverse effects for diabetic complications. JAMA. 2002;288(20): Advanced Studies in Ophthalmology 11
5 ment of DR. The effects of PKC inhibition using ruboxistaurin were evaluated in diabetic rats. The vascular permeability of blood vessels within the retina increased markedly in untreated diabetic rats, and this increase was prevented when the animals were treated with a PKC-β inhibitor. 26 More recently, the effects of PKC have been examined in transgenic animals that overexpress PKC. The overexpression of PKC in these animals simulates the effects of diabetes on PKC activity in the retina without inducing diabetes. Early diabetes-like changes were observed in the retinas of these animals, including microaneurysms, venous beading, pericyte ghosts, and acellular capillaries (King GL, personal communication). Confocal microscopy revealed the presence of venous loops, which are characteristic of early DR and are not seen in normal control animals. A significant relationship between PKC activity and DR has also been observed in patients with diabetes. In studies conducted at the Beetham Eye Institute, patients with various levels of DR severity have undergone evaluation for the activation of PKC-β in their monocytes (Aiello et al, unpublished observations). This research has demonstrated a very strong correlation between more advanced DR and greater PKC activation in the blood cells of these patients, suggesting a relationship between PKC activation and the development of NPDR or DME in patients with diabetes. Recent research suggests that VEGF is also important in the development of DR. VEGF is a homodimeric glycoprotein that is relatively selective for endothelial cells. 1 It affects both angiogenesis and vasopermeability. 27 It is produced by numerous cell types within the eye and is diffusible within the eye. 1,26 The expression of VEGF is increased by hypoxia, and is closely correlated with neovascularization and ischemic retinal disorders including DR. 28 The concentration of VEGF in the vitreous fluid is very high in patients with diabetes who have active PDR, but not in nondiabetic patients or in patients who have diabetes but do not have active PDR. 28 VEGF is believed to produce retinal complications in diabetes as the result of a multistep process. 27 VEGF first binds to high-affinity receptors located on endothelial cells. This receptor binding activates several intracellular signaling pathways that directly or indirectly increase PKC activity, including mediators phospholipase C, diacylglycerol, and inositol triphosphate. Increased activation of PKC ultimately results in increased cellular proliferation and vascular permeability. Numerous studies are being conducted to evaluate these treatments, including PKC inhibitors, VEGF inhibitors, and intravitreal steroids Several of these studies are summarized in Table 3. SUMMARY AND CONCLUSIONS The natural history of DR has been well established in a number of large clinical trials conducted over the last several decades. The development of a simplified clinical rating scale for the evaluation of DR and DME should make it easier for clinicians to communicate their findings with each other. There have been a number of recent advances in understanding the mechanisms of DR, including the identification of growth factors and intracellular signaling pathways that stimulate neovascularization and increase vascular permeability. The identification of these biochemical pathways has suggested a number of new therapeutic approaches for the prevention or treatment of DR, many of which are currently being evaluated in multicenter controlled clinical trials. Table 3. Experimental Treatments Currently Being Evaluated for Diabetic Retinopathy in Clinical Trials Agent Action Indication Status DRS (ruboxistaurin) Oral, once-daily PDR Phase 2/3 PKC-β inhibitor NPDR completed DMES (ruboxistaurin) Oral, once-daily DME Phase 2/3 PKC-β inhibitor completed Pegaptanib Intravitreal aptamer DME Phase 2 VEGF inhibitor completed rhufab V2 Intravitreal human- DME Phase 3 ized anti-vegf antibody fragment Fluorocinolone Intravitreal steroid DME Phase 3 acetonide sustained-release implant Triamacinolone Intravitral steroid DME Phase 3 acetonide injection ongoing Dexamethasone Intravitreal steroid, DME Phase 3 biodegradable, sustained-release implant PKC = protein kinase C; PDR = proliferative diabetic retinopathy; DRS = Diabetic Retinopathy Study; NPDR = nonproliferative diabetic retinopathy; DMES = Diabetic Macular Edema Study; DME = diabetic macular edema; VEGF = vascular endothelial growth factor. 12 Vol. 2, No. 1 May 2005
6 REFERENCES 1. Aiello LP, Cahill MT, Cavallerano JD. Growth factors and protein kinase C inhibitors as novel therapies for the medical management of diabetic retinopathy. Eye. 2004; 18(2): Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21(1): Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care. 1994;17(8): Javitt JC, Aiello LP. Cost effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 1996;124(1, pt 2): Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: Diabetes Care. 2000; 23(9): American Diabetes Association. Diabetes Facts. The Dangerous Toll of Diabetes. Available at: diabetes.org. 7. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in Diabetes Care. 1998;21(2): King H, Aubert RE, Herman WH. Global burden of diabetes, : prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9): Diabetes in America, Second Edition. National Diabetes Data Group. National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases; NIH publication Blindness caused by diabetes Massachusetts, MMWR Morb Mortal Wkly Rep. 1996; 45(43): Bradley RF, Rees SB, Fager CA. Pituitary ablation in the treatment of diabetic retinopathy. Med Clin North Am. 1965;49: The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol. 1976;81(4): Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Study report number 1. Arch Ophthalmol. 1985;103(12): Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology. 1985;92(4): The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14): UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131): Erratum in: Lancet. 1999;354(9178): Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9): Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98(5 suppl): Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98(5, suppl): Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9): Diabetic retinopathy: position statement. American Diabetes Association. Diabetes Care. 1998;21(1): Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98(5, suppl): Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288(20): Donnelly R, Idris I, Forrester JV. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol. 2004;88(1): Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47(6): Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997; 46(9): Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effects on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98(9): Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22): Aiello LP, Davis MD, Milton RC. Initial results of the protein kinase C β inhibitor diabetic macular edema study (PKC- DMES). Diabetologia. 2003;46(suppl 2):A Milton RC, Aiello LP, Davis MD, Sheetz MJ, Arora V, Vignati L. Initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS). Diabetologia. 2003;46(suppl 2):A Vinores SA. Technology evaluation: pegatanib, Eyetech/Pfizer. Curr Opin Mol Ther. 2003;5(6): Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3): Ciulla TA, Walker JD, Fong DS, Criswell MH. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol. 2004;15(3): Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000;41(11): Hainsworth DP, Pearson PA, Conklin JD, Ashton P. Sustained release intravitreal dexamethasone. J Ocul Pharmacol Ther. 1996;12(1):57-63 Advanced Studies in Ophthalmology 13
Diabetic retinopathy (DR) represents a
THE MOLECULAR BIOLOGY OF DIABETIC RETINOPATHY: OPPORTUNITIES FOR THERAPEUTIC INTERVENTION Lloyd P. Aiello, MD, PhD ABSTRACT Hyperglycemia is the principal underlying cause of diabetic microvascular complications,
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationINTRODUCTION AND SYMPTOMS
CHAPTER 1 INTRODUCTION AND SYMPTOMS Introduction of Diabetic Retinopathy Diabetic retinopathy (DR) is a potentially blinding complication of diabetes. It is defined as presence of one or more definite
More informationEyes on Diabetics: How to Avoid Blindness in Diabetic Patient
Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient Rova Virgana FK Unpad Pusat Mata Nasional RS Mata Cicendo Bandung Eye Center (Hospital and Clinic) PIT IDI Jabar 2018 Keys Facts from WHO
More informationEpidemiology and Pathophysiology of Diabetic Retinopathy
Epidemiology and Pathophysiology of Diabetic Retinopathy Vincent Reppucci, MD Director, Retina Service Mt. Sinai St. Luke s-roosevelt Hospital Attending Physician, Retina Service New York Eye and Ear Infirmary
More informationDiabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012
Diabetic Retinopathy Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Outline Statistics Anatomy Categories Assessment Management Risk factors What do you need to do? Objectives Summarize the
More informationDiabetic retinopathy (DR) progressively
FOCUS ON DIABETIC MACULAR EDEMA * Frederick L. Ferris III, MD ABSTRACT The current state of treatment for diabetic macular edema (DME) is focused on slowing the rate of vision loss through assessment of
More informationMolecular Biology of Diabetic Retinopathy
Opportunities for Therapeutic Intervention: Molecular Biology of Diabetic Retinopathy Jointly sponsored by The Dulaney Foundation and DIABETIC MICROVASCULAR COMPLICATIONS TODAY. Release Date: January 2006.
More informationPART 1: GENERAL RETINAL ANATOMY
PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is
More informationNew Developments in the treatment of Diabetic Retinopathy
New Developments in the treatment of Diabetic Retinopathy B. Jeroen Klevering University Medical Centre Nijmegen - The Netherlands Topics Management of diabetic retinopathy Interventions a. primary (prevention)
More informationDiabetic and the Eye: An Introduction
Diabetic and the Eye: An Introduction Lawrence Iu FRCSEd (Ophth), FCOphthHK, FHKAM (Ophthalmology) Department of Ophthalmology, Grantham Hospital & Queen Mary Hospital Background Diabetes mellitus (DM)
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus, formerly known as insulin-dependent diabetes mellitus, and non-insulin diabetes mellitus, respectively.
More informationPROCEEDINGS NEW TRENDS IN THE MANAGEMENT OF DIABETIC RETINOPATHY* Paul M. Dodson, MD, FRCP, FRCOphth ABSTRACT
NEW TRENDS IN THE MANAGEMENT OF DIABETIC RETINOPATHY Paul M. Dodson, MD, FRCP, FRCOphth ABSTRACT Based on a presentation given by Dr Dodson at a symposium held in conjunction with the 12th International
More informationDiabetic Management beyond traditional risk factors and LDL-C control: Can we improve macro and microvascular risks?
Retinopathy Diabetes has a negative effect on eyes in many ways, increasing the risk of cataracts for example, but the most common and serious ocular complication of diabetes is retinopathy. Diabetic retinopathy
More informationDiabetic Retinopathy A Presentation for the Public
Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are
More informationFacts About Diabetic Eye Disease
Facts About Diabetic Eye Disease Points to Remember 1. Diabetic eye disease comprises a group of eye conditions that affect people with diabetes. These conditions include diabetic retinopathy, diabetic
More informationDiabetic Retinopatathy
Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced
More informationDiabetic retinopathy (DR) is the leading PROCEEDINGS EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY*
EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY* Lloyd Paul Aiello, MD, PhD, and Jennifer K. Sun, MD, MPH ABSTRACT There is a wide array of research into the pathophysiology and treatment
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes mellitus is one of the leading causes of irreversible blindness worldwide. In the United States, it is the most common cause of blindness in people younger than 65 years.
More informationThe retinal renin-angiotensin system: implications for therapy in diabetic retinopathy
(2002) 16, S42 S46 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh : implications for therapy in diabetic retinopathy AK Sjølie 1 and N Chaturvedi 2 1 Department
More informationPreventing Avoidable Vision loss from Diabetic Retinopathy in Indian Country
Diabetes in Indian Country- 2017 Preventing Avoidable Vision loss from Diabetic Retinopathy in Indian Country Albuquerque, NM 20 September2017 Mark B. Horton, OD, MD Director, IHS/JVN Teleophthalmology
More informationDiabetic retinopathy (DR) was first PROCEEDINGS DIABETIC RETINOPATHY * Ronald Klein, MD, MPH ABSTRACT
DIABETIC RETINOPATHY * Ronald Klein, MD, MPH ABSTRACT Diabetic retinopathy (DR) is characterized by the development of retinal microaneurysms, hemorrhages, deposits of leaked lipoproteins (hard exudates),
More informationThe Human Eye. Cornea Iris. Pupil. Lens. Retina
The Retina Thin layer of light-sensitive tissue at the back of the eye (the film of the camera). Light rays are focused on the retina then transmitted to the brain. The macula is the very small area in
More informationMarcus Gonzales, OD, FAAO Cedar Springs Eye Clinic
Marcus Gonzales, OD, FAAO Cedar Springs Eye Clinic 25.6 million adults 11.3% of the adult population 10.9 million adults 65 years and older 26.9% of this age population 79 million people are Pre-diabetic!!
More informationLecture 19 Summary Gestational Diabetes and Complications of Diabetes. Gestational diabetes;
Lecture 19 Summary Gestational Diabetes and Complications of Diabetes Gestational diabetes; - Type of diabetes that only develops during pregnancy Usually diagnosed in late pregnancy Causes high blood
More informationJay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington
Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec
More informationThe Natural History of Diabetic Retinopathy and How Primary Care Makes A Difference
The Natural History of Diabetic Retinopathy and How Primary Care Makes A Difference We will discuss - How exactly does blood sugar control affect retinopathy? - What are other factors that we measure in
More informationGuidelines for the Management of Diabetic Retinopathy for the Internist
Visual Disorder Guidelines for the Management of Diabetic Retinopathy for the Internist JMAJ 45(1): 1 7, 2002 Sadao HORI Professor, Department of Ophthalmology, Tokyo Women s Medical University Abstract:
More informationMeasures have been taken, by the Utah Department of Health, Bureau of Health Promotions, to ensure no conflict of interest in this activity.
Measures have been taken, by the Utah Department of Health, Bureau of Health Promotions, to ensure no conflict of interest in this activity. CNE/CPE/CEU s are available for this live webinar. You must
More informationDiabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
More informationDIABETIC RETINOPATHY
DIABETIC RETINOPATHY C. L. B. Canny, MD FRCSC Diabetic retinopathy is the most serious eye manifestation of diabetes and is responsible for most of the blindness caused by diabetes. Diabetic retinopathy
More informationAbstract. Introduction. Original paper. Comparison of screening for diabetic retinopathy by non-specialists and specialists
Comparison of screening for diabetic retinopathy by non-specialists and specialists Effectiveness of screening for diabetic retinopathy by nonspecialist doctors: the importance of physician-ophthalmologist
More informationEffect of Ruboxistaurin on Blood Retinal Barrier Permeability in Relation to Severity of Leakage in Diabetic Macular Edema
Effect of Ruboxistaurin on Blood Retinal Barrier in Relation to Severity of Leakage in Diabetic Macular Edema The Harvard community has made this article openly available. Please share how this access
More informationDiabetes Care 24: , 2001
Pathophysiology/Complications O R I G I N A L A R T I C L E Prevalence and Significance of Retinopathy in Subjects With Type 1 Diabetes of Less Than 5 Years Duration Screened for the Diabetes Control and
More informationIn its initial report, the Early Treatment Diabetic Retinopathy. A Severity Scale for Diabetic Macular Edema Developed from ETDRS Data
A Severity Scale for Diabetic Macular Edema Developed from ETDRS Data Ronald E. Gangnon, 1,2 Matthew D. Davis, 3 Larry D. Hubbard, 3 Lloyd M. Aiello, 4 Emily Y. Chew, 5 Frederick L. Ferris III, 5 Marian
More informationEyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy. George Bresnick MD MPA Jorge Cuadros OD PhD
EyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy George Bresnick MD MPA Jorge Cuadros OD PhD Anatomy of the eye: 3 Normal Retina Retinal Arcades Macula Optic
More informationROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS
ORIGINAL ARTICLE ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS Aggarwal Somesh VP 1, Shah Sonali N 2, Bharwada Rekha M 3,
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationPROCEEDINGS THE IMPORTANCE OF ENDOTHELIAL DAMAGE: DIABETIC RETINOPATHY* Massimo Porta, MD, PhD ABSTRACT
THE IMPORTANCE OF ENDOTHELIAL DAMAGE: DIABETIC RETINOPATHY* Massimo Porta, MD, PhD ABSTRACT Diabetic retinopathy is the leading cause of blindness in adults of working age in industrialized countries and
More informationMANAGING DIABETIC RETINOPATHY. <Your Hospital Name> <Your Logo>
MANAGING DIABETIC RETINOPATHY It s difficult living with Diabetes Mellitus. Ask any diabetic... Their lives are centered around meal plans, glucose levels, and insulin
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationClinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.
1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417
More informationBrampton Hurontario Street Brampton, ON L6Y 0P6
Diabetic Retinopathy What is Diabetic Retinopathy Diabetic retinopathy is one of the leading causes of blindness world-wide. Diabetes damages blood vessels in many organs of the body including the eyes.
More informationEFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA
Basrah Journal Of Surgery EFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA Salah Zuhair Abed Al-Asadi MB,ChB, FICMS, Lecturer, Department of Surgery, College
More informationControl of Systemic Factors Can Preserve Vision in Diabetic Retinopathy
dmcjuly05_cme_dr 7/28/05 9:19 AM Page 38 Control of Systemic Factors Can Preserve Vision in Diabetic Retinopathy Jointly sponsored by The Dulaney Foundation and Diabetic Microvascular Complications Today.
More informationDiabetic Retinopathy
Diabetic Retinopathy Overview This presentation covers the following topics: Definitions Epidemiology of diabetic retinopathy Evidence for public health approaches Screening for diabetic retinopathy Health
More informationFREQUENCY OF DIABETIC RETINOPATHY IN A TERTIARY CARE HOSPITAL USING DIGITAL RETINAL IMAGING TECHNOLOGY
ORIGINAL ARTICLE FREQUENCY OF DIABETIC RETINOPATHY IN A TERTIARY CARE HOSPITAL USING DIGITAL RETINAL IMAGING TECHNOLOGY INTRODUCTION As more and more people are being affected with diabetes and with poor
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost
More informationFundus Fluorescein Angiography in Diabetic Retinopathy: Correlation of Angiographic Findings to the Clinical Maculopathy Abstract: Purpose:
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 2 Ver. XII (Feb. 2016), PP 80-88 www.iosrjournals.org Fundus Fluorescein Angiography in Diabetic
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More information10/8/13. the diabetes epidemic: strategies for saving sight. financial disclo$ure. unlabeled-investigative use disclosure
10/8/13 ASORN 2013 Annual Meeting New Orleans, LA the diabetes epidemic: strategies for saving sight Kate Goldblum, CNP financial disclo$ure I have no financial interests relevant to my presentation. unlabeled-investigative
More informationEyePACS Grading System (Part 2): Detecting Presence and Severity of Background (Non-Proliferative) Diabetic Retinopathy Lesion
EyePACS Grading System (Part 2): Detecting Presence and Severity of Background (Non-Proliferative) Diabetic Retinopathy Lesion George Bresnick MD MPA Jorge Cuadros OD PhD Anatomy of the eye: 3 Normal Retina
More informationDiabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec
RUIS McGILL VIRTUAL HEALTH AND SOCIAL SERVICES CENTRE (CvSSS) SIMPLIFYING TELEHEALTH! Diabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec Nurse and Imager Training Prepared
More informationDiabesity A Public Health Crisis: AOA Evidence Based Translation to Care Series
Diabesity A Public Health Crisis: AOA Evidence Based Translation to Care Series Joseph J. Pizzimenti, OD, FAAO Associate Professor Nova Southeastern University The Eye Care Institute pizzimen@nova.edu
More informationBY BERNARD ZINMAN, MD
Understanding the Relationship Between Hyperglycemia and Microvascular Complications Jointly sponsored by The Dulaney Foundation and DIABETIC MICROVASCULAR COMPLICATIONS TODAY. Release Date: August 2006.
More informationDiabetes & Your Eyes
Diabetes & Your Eyes Diabetes is a disease that occurs when the pancreas does not secrete enough insulin or the body is unable to process it properly. Insulin is the hormone that regulates the level of
More informationDiabetic eye disease. Diabetic retinopathy. Sam S. Dahr, M.D. Retina Center of Oklahoma.
Diabetic eye disease Sam S. Dahr, M.D. Retina Center of Oklahoma www.rcoklahoma.com Downloaded from: The Retina (on 28 May 2007 12:48 AM) 2007 Elsevier Diabetic retinopathy Downloaded from: The Retina
More informationDiabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?
Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? Diabetic retinopathy affects 8 million Americans with diabetes. A leading cause of blindness in American adults, it is caused by damage to the small blood
More informationDiabetic Retinopathy Screening in Hong Kong. Dr. Rita Gangwani M.S, FRCS (Ophth), FCOphth(HK), FHKAM Eye Institute, The University of Hong Kong
Diabetic Retinopathy Screening in Hong Kong Dr. Rita Gangwani M.S, FRCS (Ophth), FCOphth(HK), FHKAM Eye Institute, The University of Hong Kong Co-Investigators Prof. David Wong Prof. Sarah McGhee Dr. Wico
More informationRetinopathy in a diabetic population
Kathmandu University Medical Journal (2007), Vol. 5, No. 2, Issue 18, 204-209 Retinopathy in a diabetic population Shrestha S 1, Malla OK 2, Karki DB 3, Byanju RN 4 2 Fellow of NAMS, 3 Professor, NAMS,
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationJMSCR Vol. 03 Issue 08 Page August 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x DOI: http://dx.doi.org/10.18535/jmscr/v3i8.05 Study of Prevalence of Diabetic Retinopathy in Already Confirmed Diabetic Patients Who Were
More informationProposed International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales
Proposed International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales C. P. Wilkinson, MD, 1 Frederick L. Ferris, III, MD, 2 Ronald E. Klein, MD, MPH, 3 Paul P. Lee, MD,
More informationPrevalence of diabetic retinopathy in diabetics of rural population belonging to Ramanagara and Chikkaballapura districts of Karnataka
International Journal of Scientific and Research Publications, Volume 5, Issue 3, March 215 1 ISSN 225-3153 Prevalence of diabetic retinopathy in diabetics of rural population belonging to Ramanagara and
More informationDIABETIC RETINOPATHY: FROM EVIDENCE AND PROMISE TO REAL LIFE OBSERVATIONS
DIABETIC RETINOPATHY: FROM EVIDENCE AND PROMISE TO REAL LIFE OBSERVATIONS Dr. Sehnaz Karadeniz Diabetic retinopathy is one of the most feared complications of diabetes and one of the leading causes of
More informationDiabetic Retinopathy
Diabetic Retinopathy Introduction People with diabetes are more likely to have eye problems that can lead to blindness. Diabetic retinopathy is a disease of the eye s retina that is caused by diabetes.
More informationPROGRESSION OF DIABETIC RETINOPATHY FOLLOWING CATARACT SURGERY
PROGRESSION OF DIABETIC RETINOPATHY FOLLOWING CATARACT SURGERY Yayan Heryanto, Iwan Sovani, Arief Kartasasmita, Erwin Iskandar, Djonggi Panggabean. Dept. of Ophthalmology Medical Faculty Unpad, Cicendo
More informationPathology of endocrine pancreas. By: Shifaa Alqa qa
Pathology of endocrine pancreas By: Shifaa Alqa qa major cell types: Beta ----- insulin Alpha ----- glucagon Delta ----- somatostatin PP (pancreatic polypeptide) cells ------ VIP DIABETES MELLITUS Normal
More informationMedical Retina 2011 Nicholas Lee
Medical Retina 2011 Nicholas Lee 1 Diabetic Retinopathy Epidemiology 1000 registered blind each year 2% diabetics registered as blind (8% of all Blind Registrations) 42% with Mild Background DR will progress
More informationLong-Term Visual Outcome in Proliferative Diabetic Retinopathy Patients After Panretinal Photocoagulation
Long-Term Visual Outcome in Proliferative Diabetic Retinopathy Patients After Panretinal Photocoagulation Murat Dogru, Makoto Nakamura, Masanori Inoue and Misao Yamamoto Department of Ophthalmology, Kobe
More informationDIABETES AND YOUR EYES. Presented by Dr. Andrea Hagler
DIABETES AND YOUR EYES Presented by Dr. Andrea Hagler Tahlequah, OK Forest Grove, OR Brief Review of Diabetes The body s endocrine system is responsible for regulating growth, reproduction, and tissue
More informationX-Plain Diabetic Retinopathy Reference Summary
X-Plain Diabetic Retinopathy Reference Summary Introduction Patients with diabetes are more likely to have eye problems that can lead to blindness. Diabetic retinopathy is a disease of the eye s retina
More informationParadigm Shift in the treatment of Diabetic Retinopathy. Haytham I. S. Salti, MD Associate Professor
Paradigm Shift in the treatment of Diabetic Retinopathy Haytham I. S. Salti, MD Associate Professor Disclosure No financial interests related to the subject matter of this talk This presentation includes
More informationDiabetic Retinopathy
Diabetic Retinopathy Secretary for Quality of Care Anne L. Coleman, MD, PhD Academy Staff Nicholas P. Emptage, MAE Doris Mizuiri Shannon Kealey, MLS Flora C. Lum, MD Medical Editor: Design: Approved by:
More informationDiabetes, particularly diabetic retinopathy, is
Chapter 14 Vision Disorders in Diabetes Ronald Klein, MD, MPH, and Barbara E.K. Klein, MD, MPH SUMMARY Diabetes, particularly diabetic retinopathy, is the leading cause of new cases of blindness in people
More informationFactors Associated with Visual Outcome after Photocoagulation for Diabetic Retinopathy
Investigative Ophthalmology & Visual Science, Vol. 30, No. 1, January 1989 Copyright Association for Research in Vision and Ophthalmology Factors Associated with Visual Outcome after Photocoagulation for
More informationDiabetic retinopathy damage to the blood vessels in the retina. Cataract clouding of the eye s lens. Cataracts develop at an earlier age in people
Diabetic Retinopathy What is diabetic eye disease? Diabetic eye disease refers to a group of eye problems that people with diabetes may face as a complication of diabetes. All can cause severe vision loss
More informationClinical biomicroscopy versus fluorescein angiography: Effectiveness and sensitivity in detecting diabetic retinopathy
European Journal of Ophthalmology / Vol. 17 no. 1, 2007 / pp. 84-88 Clinical biomicroscopy versus fluorescein angiography: Effectiveness and sensitivity in detecting diabetic retinopathy S.S. KHALAF, M.D.
More informationMAGNITUDE OF DIABETIC EYE DISEASE IN INDIA
Dear Doctor This booklet contains information about your role as a physician in preventing blindness in your diabetic patients. You are the first point of contact for your diabetic patients. You see them
More informationInflammatory basis of diabetic retinopathy. Tim Kern, PhD Case Western Reserve University and Stokes VA Hospital, Cleveland, OH
Inflammatory basis of diabetic retinopathy Tim Kern, PhD Case Western Reserve University and Stokes VA Hospital, Cleveland, OH Diabetic retinopathy currently is diagnosed based on vascular abnormalities
More informationClassification of diabetic retinopathy and diabetic macular edema
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.4239/wjd.v4.i6.290 World J Diabetes 2013 December 15; 4(6): 290-294 ISSN 1948-9358 (online) 2013 Baishideng Publishing Group
More informationDiabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel
Miss Vasuki Sivagnanavel Consultant Ophthalmologist An update on Diabetic maculopathy Despite advances in the management of diabetes, diabetic retinopathy is already the commonest cause of blindness among
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationCOMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY
Original Article COMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY Aggarwal Somesh V 1, Shah Sonali N 2, Bharwada Rekha
More informationCLINICAL SCIENCES. Results After Lens Extraction in Patients With Diabetic Retinopathy. Early Treatment Diabetic Retinopathy Study Report Number 25
CLINICAL SCIENCES Results After Lens Extraction in Patients With Diabetic Retinopathy Early Treatment Diabetic Retinopathy Study Report Number 25 Emily Y. Chew, MD; William E. Benson, MD; Nancy A. Remaley,
More informationFRANZCO, MD, MBBS. Royal Darwin Hospital
Diabetes and Eye By Dr. Nishantha Wijesinghe FRANZCO, MD, MBBS Consultant Ophthalmologist Royal Darwin Hospital 98% of Diabetics do not need to suffer from severe visual loss Yet Diabetic eye disease is
More informationCase Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema V Swetha E Jeganathan 1,2 * and Karen Madill 3 1 Department of Ophthalmology,
More informationDr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre
Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre 11:00-11:55 WS #115: The Revolution in Macular Degeneration Management 12:05-13:00 WS #127: The Revolution in Macular
More informationDiabetic Retinopathy Frequently Asked Questions
Diabetic Retinopathy Frequently Asked Questions Q.Who is at risk of diabetic retinopathy? Diabetic retinopathy is a highly vascularised eye complication of both insulin dependent and non-insulin dependent
More informationSlide notes: The major chronic complications of diabetes mellitus are described here. Among these, microvascular complications have an important
1 2 The major chronic complications of diabetes mellitus are described here. Among these, microvascular complications have an important role. They comprise microangiopathy, diabetic retinopathy, diabetic
More informationRANZCO Screening and Referral Pathway for Diabetic Retinopathy #
RANZCO Screening and Referral Pathway for Diabetic Retinopathy # Patient Presents a. Screen for Diabetic Retinopathy every 2 years b. Begin screening at diagnosis of Diabetes * Clinical Modifi ers Yearly
More informationStudy of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema
Original Research Article Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Neha Kantilal Desai 1,*, Somesh Vedprakash Aggarwal 2, Sonali
More informationOCCLUSIVE VASCULAR DISORDERS OF THE RETINA
OCCLUSIVE VASCULAR DISORDERS OF THE RETINA Learning outcomes By the end of this lecture the students would be able to Classify occlusive vascular disorders (OVD) of the retina. Correlate the clinical features
More informationA Patient s Guide to Diabetic Retinopathy
Diabetic Retinopathy A Patient s Guide to Diabetic Retinopathy 840 Walnut Street, Philadelphia PA 19107 www.willseye.org Diabetic Retinopathy 1. Definition Diabetic retinopathy is a complication of diabetes
More informationMild NPDR. Moderate NPDR. Severe NPDR
Diabetic retinopathy Diabetic retinopathy is the most common cause of blindness in adults aged 35-65 years-old. Hyperglycaemia is thought to cause increased retinal blood flow and abnormal metabolism in
More informationScott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012
Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012 Proliferative Diabetic Retinopathy Laser Treatments Medical Treatment Surgical Treatment Diabetic Macular Edema Laser
More informationNEPTUNE RED BANK BRICK
NEPTUNE RED BANK BRICK Diabetes & The Eye Diabetics are more likely to develop Cataracts at a younger age. Diabetics are twice as likely to develop Glaucoma when compared to non-diabetics. The primary
More informationAlthough photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *
PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Evangelos S. Gragoudas, MD ABSTRACT In December 24, the US Food and Drug Administration (FDA) approved pegaptanib sodium. Pegaptanib
More informationOutline. Preventing & Treating Diabetes Related Blindness. Eye Care Center Doctors. Justin Kanoff, MD. Eye Care Center of Northern Colorado
Outline Preventing & Treating Diabetes Related Blindness Justin Kanoff, MD Eye Care Center of Northern Colorado 303 974 4302 Introduction to Eye Care Center of Northern Colorado How the eye works Eye problems
More informationVISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT
The Professional Medical Journal DOI: 10.17957/TPMJ/16.2856 ORIGINAL PROF-2856 VISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT 1. MBBS.FCPS Assistant Professor Ophthalmology Independent
More information